Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

David A. Qualls; Nicholas Lambert; Paolo F. Caimi; Mwanasha Merrill; Priyanka Pullarkat; Richard C. Godby; David A. Bond; Graham T. Wehmeyer; Jason Romancik; Behzad Amoozgar; Lori Leslie; Loretta J. Nastoupil; Jennifer L. Crombie; Jeremy S. Abramson; Arushi Khurana; Grzegorz S. Nowakowski; Kami Maddocks; Sarah C. Rutherford; Brad Kahl; Michelle Okwali; Michael J. Buege; Venkatraman Seshan; Connie L. Batlevi; Gilles Salles

doi:10.1182/blood.2023021274

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

David A. Qualls, Nicholas Lambert, Paolo F. Caimi, Mwanasha Merrill, Priyanka Pullarkat, Richard C. Godby, David A. Bond, Graham T. Wehmeyer, Jason Romancik, Behzad Amoozgar, Lori Leslie, Loretta J. Nastoupil, Jennifer L. Crombie, Jeremy S. Abramson, Arushi Khurana, Grzegorz S. Nowakowski, Kami Maddocks, Sarah C. Rutherford, Brad Kahl, Michelle OkwaliMichael J. Buege, Venkatraman Seshan, Connie L. Batlevi, Gilles Salles

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

Original language	English
Pages (from-to)	2327-2331
Number of pages	5
Journal	Blood
Volume	142
Issue number	26
DOIs	https://doi.org/10.1182/blood.2023021274
State	Published - Dec 28 2023

Access to Document

10.1182/blood.2023021274

Cite this

Qualls, D. A., Lambert, N., Caimi, P. F., Merrill, M., Pullarkat, P., Godby, R. C., Bond, D. A., Wehmeyer, G. T., Romancik, J., Amoozgar, B., Leslie, L., Nastoupil, L. J., Crombie, J. L., Abramson, J. S., Khurana, A., Nowakowski, G. S., Maddocks, K., Rutherford, S. C., Kahl, B., ... Salles, G. (2023). Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood, 142(26), 2327-2331. https://doi.org/10.1182/blood.2023021274

@article{b8dc16547b6d428287f06ff38eabda61,

title = "Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study",

abstract = "In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.",

author = "Qualls, {David A.} and Nicholas Lambert and Caimi, {Paolo F.} and Mwanasha Merrill and Priyanka Pullarkat and Godby, {Richard C.} and Bond, {David A.} and Wehmeyer, {Graham T.} and Jason Romancik and Behzad Amoozgar and Lori Leslie and Nastoupil, {Loretta J.} and Crombie, {Jennifer L.} and Abramson, {Jeremy S.} and Arushi Khurana and Nowakowski, {Grzegorz S.} and Kami Maddocks and Rutherford, {Sarah C.} and Brad Kahl and Michelle Okwali and Buege, {Michael J.} and Venkatraman Seshan and Batlevi, {Connie L.} and Gilles Salles",

note = "Publisher Copyright: {\textcopyright} 2023 The American Society of Hematology",

year = "2023",

month = dec,

day = "28",

doi = "10.1182/blood.2023021274",

language = "English",

volume = "142",

pages = "2327--2331",

journal = "Blood",

issn = "0006-4971",

number = "26",

}

Qualls, DA, Lambert, N, Caimi, PF, Merrill, M, Pullarkat, P, Godby, RC, Bond, DA, Wehmeyer, GT, Romancik, J, Amoozgar, B, Leslie, L, Nastoupil, LJ, Crombie, JL, Abramson, JS, Khurana, A, Nowakowski, GS, Maddocks, K, Rutherford, SC, Kahl, B, Okwali, M, Buege, MJ, Seshan, V, Batlevi, CL & Salles, G 2023, 'Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study', Blood, vol. 142, no. 26, pp. 2327-2331. https://doi.org/10.1182/blood.2023021274

TY - JOUR

T1 - Tafasitamab and lenalidomide in large B-cell lymphoma

T2 - real-world outcomes in a multicenter retrospective study

AU - Qualls, David A.

AU - Lambert, Nicholas

AU - Caimi, Paolo F.

AU - Merrill, Mwanasha

AU - Pullarkat, Priyanka

AU - Godby, Richard C.

AU - Bond, David A.

AU - Wehmeyer, Graham T.

AU - Romancik, Jason

AU - Amoozgar, Behzad

AU - Leslie, Lori

AU - Nastoupil, Loretta J.

AU - Crombie, Jennifer L.

AU - Abramson, Jeremy S.

AU - Khurana, Arushi

AU - Nowakowski, Grzegorz S.

AU - Maddocks, Kami

AU - Rutherford, Sarah C.

AU - Kahl, Brad

AU - Okwali, Michelle

AU - Buege, Michael J.

AU - Seshan, Venkatraman

AU - Batlevi, Connie L.

AU - Salles, Gilles

PY - 2023/12/28

Y1 - 2023/12/28

N2 - In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

AB - In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

UR - http://www.scopus.com/inward/record.url?scp=85175478290&partnerID=8YFLogxK

U2 - 10.1182/blood.2023021274

DO - 10.1182/blood.2023021274

M3 - Article

C2 - 37738563

AN - SCOPUS:85175478290

SN - 0006-4971

VL - 142

SP - 2327

EP - 2331

JO - Blood

JF - Blood

IS - 26

ER -

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this